Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesSafety Concerns with Fluoroquinolones
Annals of Pharmacotherapy, 10/19/07
Mehlhorn, A.J., et al. - Conclusion: Clinicians should be aware of possible alterations in blood glucose, QTc interval prolongation, seizures, phototoxicity, tendinopathy, or CDAD with the use of any fluoroquinolone, especially in patients with other risk factors for these conditions. Clinicians should closely monitor for these adverse effects and appropriately adjust doses to minimize these risks. To provide safe treatment for patients needing antibiotic therapy, an assessment of the risk-benefit ratio may be warranted in the decision to use a fluoroquinolone
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Divalproex Sodium-Induced Eosinophilic Pleural Effusion
American Journal of Therapeutics, 12/04/09
Lithium and thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 12/04/09
Acute Generalized Exanthematous Pustulosis: A Rare Clinical Entity With Use of Piperacillin/Tazobactam
American Journal of Therapeutics, 12/04/09
Sponsor
Article Search
Sponsor
Sponsor